...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: USA ZHCLF investors

So who issued the 63 m shares, ZCC or ZEL.

Zenith Capital Corp. (formerly named Zenith Epigenetics Corp. prior to the name change Aug 2, 2016, not to be confused with Zenith Epigenetics Ltd., a whole owned subsidiary of Zenith Capital Corp.) issued those shares by doing private placements over the years since 2013.  Here is one example.......

Zenith Capital Closes $5.7 Million Private Placement

 

August 31, 2018

 

CALGARY, Alberta, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zenith Capital Corp. ("Zenith" or the "Company") today announced that it has closed a private placement of approximately 2.2 million units at a price of US$2.00 per unit for gross proceeds of approximately $5.7 million (US$4.4 million) (the "Private Placement") with Eastern Capital Limited (“Eastern”) and other subscribers (collectively, the “Subscribers”). Each unit is comprised of one (1) common share and one-half (1/2) of a common share purchase warrant exercisable at US$3.00 per share for a period of three (3) years. The Subscribers may not trade the securities for four months.

 

Share
New Message
Please login to post a reply